RYZB Stock Overview
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RayzeBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$62.49 |
| 52 Week High | US$62.51 |
| 52 Week Low | US$17.95 |
| Beta | 0 |
| 1 Month Change | 0.66% |
| 3 Month Change | 170.29% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 160.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| RYZB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 0.5% | -0.7% |
| 1Y | n/a | 1.2% | 22.8% |
Return vs Industry: Insufficient data to determine how RYZB performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how RYZB performed against the US Market.
Price Volatility
| RYZB volatility | |
|---|---|
| RYZB Average Weekly Movement | 29.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RYZB's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine RYZB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 88 | Ken Song | rayzebio.com |
RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company’s lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC.
RayzeBio, Inc. Fundamentals Summary
| RYZB fundamental statistics | |
|---|---|
| Market cap | US$3.74b |
| Earnings (TTM) | -US$64.71m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-57.9x
P/E RatioIs RYZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RYZB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.71m |
| Earnings | -US$64.71m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did RYZB perform over the long term?
See historical performance and comparison